MGCD-516 (Sitravatinib)
-
Technical Data
Description
MGCD-516 (Sitravatinib) is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth. MGCD-516 treatment resulted in significant blockade of phosphorylation of potential driver RTKs and induced potent anti-proliferative effects in vitro. MGCD-516 treatment of tumor xenografts in vivo resulted in significant suppression of tumor growth.